Why the study?
Does aldosterone antagonism offer additional antiproteinuric benefits in patients with renal disease treated with ACE inhibitors?
Does aldosterone antagonism offer additional antiproteinuric benefits in patients with renal disease treated with ACE inhibitors?
Aldosterone antagonism provides additional antiproteinuric benefits beyond ACE inhibition in renal disease, though long-term safety data regarding hyperkalemia are needed.
Answers are grounded in this paper and cite their sources.
Supports adjunctive aldosterone antagonism for proteinuria beyond ACE inhibition; leaves open hyperkalemia risks and hard outcomes.
Purpose of review Interruption of the renin-angiotensin-aldosterone system, chiefly with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. The renoprotection offered by these agents is incomplete and far from optimal. Studying mediators of progression other than angiotensin II is therefore extremely important. The emerging role of aldosterone in progression of renal disease and the utility of its antagonism is discussed here. Recent findings The experimental evidence linking aldosterone to renal disease is discussed. The exciting results from clinical studies employing mineralocorticoid receptor blockers are also described. Summary Aldosterone antagonism offers additional antiproteinuric benefits to those achieved with angiotensin-converting enzyme inhibition. Long-term trials addressing effectiveness and safety, especially in regards to hyperkalemia, are greatly needed.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: